Opioid overdose can be reversed with timely administration of naloxone. In Australia, naloxone was rescheduled from prescription only (S4) to pharmacist only over-the-counter (OTC, S3) in February 2016, increasing access for the general public. A key barrier to naloxone supply by pharmacists is a lack of knowledge, highlighting the role of pharmacist education. Community pharmacists' education, experience, and training preferences related to naloxone provision, overdose, and substance use disorder were examined.
Introduction
Deaths from opioid overdose are increasing, yet opioid overdose can be reversed with timely administration of naloxone (1, 2) . Naloxone is recommended to be widely available by the World Health Organization (3) , with the intention that it is administered at a later time by a trained layperson who witnesses an overdose (also known as 'take-home' naloxone, or THN). Internationally, pharmacists are recognized as potential educators and distributers of naloxone to the community (4, 5) but few countries are yet to widely distribute naloxone in this setting. According to available literature only Italy, Australia and some US states have naloxone available without a prescription (1) . To maximize naloxone availability through pharmacies the experiences and attitudes of pharmacists on their new roles as distributers of naloxone in the community need to be better understood.
In February 2016 in Australia, naloxone was rescheduled from prescription only (S4) to pharmacist only over the counter (OTC, S3) (1), yet OTC naloxone has not been widely taken up by community pharmacies. Previously in Australia, patients needed a prescription from their general practitioner either via traditional medical appointments, or though attendance at a specialised overdose prevention training workshop (1, 6) . The rescheduling required a change to the Standard for the Uniform Scheduling of Medicines and Poisons legislation administered by the Australian Therapeutic Goods Administration (TGA) in order to 'down-schedule' naloxone from its existing Schedule 4 status as a 'prescription only' medicine to a 'pharmacist only' (Schedule 3) medicine. Schedule 3, or OTC medicines, are stored behind the counter and a pharmacist must be involved in the sale to ensure safe use of medicines. The down-scheduling enables pharmacists to initiate naloxone supply and allows members of the public to request naloxone from pharmacies.
In Australia, opioid overdose deaths have increased each year since 2006, with a 64% increase in overdose deaths in the ten years leading up to 2015 (9) . On a global level, Australia has a higher than average drug mortality rate with opioids being the leading cause of drug-related death (10) . In most cases, these deaths are accidental and preventable and population level responses are required to reverse these concerning trends. The rescheduling of naloxone in Australia recognises the potential role of pharmacists in overdose prevention including as educators and distributers of naloxone (4, 5, 11, 12) .
A scoping review and Australian national online survey of pharmacists completed in 2015 revealed that community pharmacists hold positive attitudes towards provision of illicit M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 3 drug-related harm reduction services, including naloxone supply (7, 8) . Yet few pharmacists appear confident in their ability to identify and train patients in administering OTC naloxone (8) . Furthermore, many pharmacists have limited knowledge of naloxone, highlighting the importance of education in this area (8) .
To better understand the educational needs and preferences of pharmacists around naloxone supply a mixed-methods study (online survey and qualitative interviews) of community pharmacists' preferences for provision of naloxone to people at risk of opioid overdose, their family, and friends was conducted. To gain further insight into the findings from the online survey data, qualitative interviews examined pharmacists' behaviors and preferences for opioid overdose prevention training, and explored facilitators and barriers to training on OTC naloxone. Three questions were addressed: 
Methods
Using a sequential explanatory mixed methods design (13) , community pharmacists' education needs in relation to naloxone and overdose prevention was investigated using two data sources:
1. Quantitative data from an existing national online survey (n = 595); and 2. Qualitative telephone interviews with a sample of those who participated in the national online survey (n=21).
Qualitative data were used to explore, in greater depth, findings from the quantitative national survey, providing validation of key findings and context to the survey results (14) .
National online survey
Previously unreported data from a national online survey undertaken in September-November 2015 (8) was analyzed. This study aimed to recruit a nationally representative sample of 10% of community pharmacies. Pharmacies were contacted by phone with the pharmacist-in-charge or pharmacist manager invited to participate, with a request to provide an email address. We sought to have one pharmacist (the pharmacist in charge) to represent the situation in each pharmacy to avoid multiple responses per pharmacy. Where pharmacists were willing to receive further information, an invitation email was sent which included a link to the participant information statement and online survey. With a response rate of 45%, 595 community pharmacists participated in the survey, representing 11% of the 5,450 operating pharmacies in Australia (8) (see Figure 1 for recruitment flow). The online survey was designed to take fewer than 20 minutes to complete (mean completion time was 26.6 minutes, median 18.7 minutes).
Pharmacists were reimbursed AUD$40 for completing the survey. This quantitative study was approved by the University of New South Wales Human Research Ethics Advisory (HREA) Panel: Social and Health Research (HC15556).
Measures
Four age groups (less than 25 years of age, 25-34 years old, 35-54 years and 55 years and above), gender, years of practice and further education about SUD after graduating were examined. All were examined as binary variables, except for years of practice which was examined as a continuous variable.
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Geographic location was classified as capital city, other metropolitan urban center (population equal to or greater than 100,000), rural location (population between 5,000 to 99,999) and remote area (population less than or equal to 5,000). Rural and remote categories were collapsed, as there were fewer respondents in these categories.
Previous experience with SUD training and confidence to supply naloxone were examined as binary variables. Current provision of opioid substitution treatment (OST) and whether the pharmacy stocked naloxone were examined as binary variables.
Confidence in ability to educate patients to recognize opioid overdose and safely administer naloxone was measured using a 7-point scale where 1 = "not at all confident" and 7 = "extremely confident".
Willingness to educate patients to recognize opioid overdose and safely administer naloxone, and to attend training were both rated by participants on a 4-point scale from "already doing this" to "not at all willing to do this". Responses were collapsed into a binary variable where participants who were "already doing this activity" and "extremely willing to do this activity" formed one group, while "somewhat willing to do this" and "not at all willing to do this" formed the other. This was due to low response numbers in the outer most two options (n<10).
Preferred format of training was examined. Seven options were offered: "face-to-face (one-to-one)", "online", "webinar", "both online and face-to-face", "would not like to receive training", "face-to-face (group)" and "written".
The time willing to spend receiving education about naloxone was offered as six groupings: "less than 5 minutes", "between 5-15 minutes", "between 16-59 minutes" "between 1-2 hours", "up to 4 hours", and "more than 4 hours".
Data were descriptively analyzed to examine pharmacists' previous continual professional education (CPD) and their willingness, time and preferences for training relating to OTC naloxone supply. Ordinal logistic regression was used to assess the associations with pharmacists confidence to educate patients in opioid overdose and administering naloxone. confidence and experiences with naloxone. Pharmacists preferences around naloxone training were descriptively explored. All analyses were conducted using SPSS Version 23.
Qualitative telephone interviews
Pharmacists who had participated in the national survey who indicated interest in participating in further research were contacted by email and invited to participate in a short telephone interview, in addition to promoting the study through professional networks.
We interviewed 21 community pharmacists from three states in Australia, Victoria (n=6), New South Wales (n=10) and Queensland (n=5). We purposively recruited for variation according to gender, age, geographic diversity as well as provision of harm reduction services. Around half (11 of 21) were female; six were aged 20-29 years, nine were 30-39 years and six were aged over 40 years. Most (16 out of 21) were from metropolitan locations (as opposed to regional or rural), eight provided Needle Syringe Program (NSP) services, and 11 provided OST services. Interviews were used to explore community pharmacists' experiences of and attitudes to providing OTC naloxone. Topics included: the role of pharmacists supporting people at risk of opioid overdose; knowledge of and attitudes to OTC naloxone provision; and required information or training. This paper is focused on their accounts of naloxone training, willingness to receive future training, as well as training preferences. Pharmacists were interviewed over the telephone using a semi-structured interview guide. A brief survey was used to collect basic demographic information.
Interviews took 30-45 minutes. Pharmacists chose whether to be reimbursed AUD$50 for their time and contribution to research or to donate AUD$50 to one of three charities. Data were collected between September 2016 and December 2016.
Interviews were digitally recorded and professionally transcribed. Transcripts were deidentified and data were analysed in NVivo 11 software using a thematic analysis (14, 15) . Preliminary analysis, including the development of a preliminary codebook, was conducted by author KLJC guided by the research questions above.
Following the steps outlined by Braun and Clarke (15) , coding and analysis of the full dataset was completed by author AO. Transcripts were read and re-read, comparing interviews for similarities and differences. Transcripts were then coded systematically to establish themes. This manuscript focusses on the findings relating to previous experiences of SUD training, confidence and willingness to supply naloxone, attitudes to training and preferences for training delivery.
Please see supplementary material for full details of questions asked in the online survey and qualitative interviews.
Results
Participant demographics. Table 1 displays the descriptive statistics for the survey participants. The 595 respondents were roughly split evenly between males and females (54% and 46%, respectively).
Respondents had been practicing for a median of 9 years (IQR: 5-21 years) with approximately half receiving training on SUD after graduating (n=288, 48%) and currently providing OST services (n=307, 52%). Despite the majority of pharmacists having heard of naloxone being used in the community for opioid reversal (n=425, 71%), only around a quarter were aware of naloxone being stocked in their pharmacy (n=136, 23%).
Associations with confidence and willingness to educate patients on opioid overdose and naloxone administration.
The majority of survey participants were either already (n=10, 2%) or extremely willing (n=471, 76%) to educate patients on opioid overdose recognition and safe naloxone administration, while the median confidence level was average (4 out of 7), with two thirds (62%) of pharmacists falling between 3 and 5 (1 being 'not at all confident' and 7 being 'extremely confident"). Confidence was associated with gender (OR 1.91, 95%CI 1.43, 2.57) with males being more confident than females ( Table 2 ). Provision of OST services, number of years practicing and confidence to educate were all associated with willingness to educate patients on overdose risk (Table 3 ). Pharmacists already providing OST services were more willing (OR 1.65, 95%CI 1.07, 2.53) as were those who were confident to educate (OR 1.45, 95%CI 1.27, 1.67). Pharmacists who had been practicing for longer were less willing to educate patients in opioid overdose and naloxone administration (OR 0.97, 95%CI 0.95, 0.99). No association was found between previous education on SUD for either willingness or confidence, whilst OST provision had no effect on confidence.
Pharmacists' willingness to attend training on naloxone and overdose prevention
Few pharmacists interviewed in the qualitative study had attended any naloxone specific training and most seemed unaware of resources or training available to assist them in providing OTC naloxone. This is illustrated in the following quotations. Overall, most pharmacists who participated in the survey were extremely willing to attend (n=471, 79%) or had already completed training about naloxone (n=8, 1%). Analysis of the survey data shows that particular demographic characteristics were associated with their willingness to attend education on opioid overdose prevention (Table 4 ). Pharmacists who had had previous education on SUD were almost twice as willing to attend training (OR 1.94, 95%CI 1.23, 3.06) than those who had not. Males were half as likely to be willing attend (OR 0.44, 95%CI 0.28 , 0.70) than females.
Each year of increased practice experience was associated with reduced odds of being willing to attend training (OR 0.96, 95% CI 0.95, 0.98). Pharmacists who were confident about educating patients in opioid overdose and administration of naloxone were significantly more willing to attend training (OR 1.31, 95% CI 1.14, 1.50). No association was found between willingness to attend training and current provision of OST or geographical location of pharmacy.
While most pharmacists were willing to attend training on opioid overdose prevention or naloxone provision, some were reluctant. Analysis of the qualitative interview data suggests that this may be, in part, because some pharmacists believe that people living with SUD are a problematic client group, and that naloxone provision is best provided in services specifically catering for people living with SUD rather than community pharmacies. The following quotations highlight these concerns. Preferred mode of delivery for training More than two thirds of the survey respondents had a preference for between 5 and 59 minutes (n=413 of 595, 69%), while fewer (n= 157 of 595, 26%) were willing to spend more than one hour on naloxone training (Table 5 ). Responses from interview participants on time willing to spend on naloxone training varied from less than five minutes to more than four hours. Pharmacists expressed availability constraints during working hours. In terms of mode of delivery, most pharmacists completing the survey preferred online/webinar training (n = 328, 55%), or face-to-face training (n = 253, 45%). Fourteen (2%) participants did not express a preference between face-to-face or online training: three (<1%) indicated a preference to attend both online and face-to-face training, six (1%) preferred written training and five (<1%) did not wish to attend any training at all (Table   4 ). In addition to their primary choice of training delivery, 32 respondents provided additional comments. The most common comment cited additional or multiple preferences (n=19), 6 stated face to face would be ideal but is often impractical (especially for rural pharmacists), 4 suggested supplementary written or online material for later review and 3 highlighted the importance for interactive sessions/ ability to ask questions.
Responses from interview participants on preferred mode of delivery also varied. Some In addition, there needs to be a consistent approach to naloxone training (for community members and professionals). Education workshops delivered in the United States highlight the importance of multi-disciplinary care and emphasize pharmacists' involvement as part of the overall patient care in opioid overdose prevention (16, 17) . One strategy would be to establish a national program, as has been achieved in Scotland, where training and distribution is coordinated across multiple community outlets (e.g., drug user organizations, drug treatment services, pharmacists) in order to maximize the reach of these initiatives (18).
Results from this study also suggests that promotion and education are needed to attract those pharmacists who are less confident in working with those living with SUD. Those with more years of experience). suggesting that that more general SUD training could be updated to include naloxone but also that training efforts on THN need to be widespread. .
Pharmacists expressed a range of preferences around how they might receive training.
Professional pharmacy organizations and pharmaceutical companies would be the preferred or expected providers of any new educational initiatives. The role of professional organizations in leadership and creation of training and guidelines is important in practice change in pharmacy (17, 19) . Respondents noted the value of a PSA protocol or Guild guideline to supplement the training, providing a step-by-step guide in when to supply or not to supply OTC naloxone. Pharmacists appeared either unaware, or unable to access, existing resources on naloxone potentially because they require membership to pharmaceutical societies to retrieve the resources, or because the availability of the resources have not been heavily promoted. Visual training aids and counselling skills were considered helpful resources. Visual, hands-on training is useful for learning about a drug that requires intramuscular administration. A range of resources exist in Australia developed by groups other the pharmaceutical industry and related professional organizations (20) . However, these do not appear to be used as a source of information by pharmacists. Further, there may be a need to expand current training resources as recent research reviewing the content of naloxone training for pharmacists highlighted the importance of educating pharmacists on how to communicate about naloxone with patients, in addition to what information should be communicated (21) . In light of low uptake of THN from community pharmacies, training that addresses communicate on these sensitive issues may be a way to improve naloxone supply in pharmacy practice. We note that pharmaceutical companies traditionally address this need. However, with no patented naloxone product consistently available at the time of the study, this had not occurred. With the emergence of new intranasal naloxone formulations this may change
Time is a common barrier when seeking to train professionals (17, (23) (24) (25) (26) . Most pharmacists preferred a short duration of training -no more than one hour. Accredited training that can be counted towards pharmacists' mandatory training requirements is one strategy that may help to overcome time barriers experienced by most pharmacists, since it is a professional requirement to allocate time to accredited training.
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A C C E P T E D ACCEPTED MANUSCRIPT 15 The availability of pharmacist training alone is unlikely to address challenges in expanding naloxone supply. The low availability of naloxone (in less than one in four pharmacies surveyed) supports that there is enormous potential to increase pharmacy involvement in this area. Furthermore, public knowledge of OTC naloxone availability needs to be enhanced in order to increase the number of patients requesting the medicine in pharmacies. Current research suggests that among people who inject drugs there has been an increase in awareness of naloxone (27) . However among the other target patient group, those prescribed opioids, there is low awareness of naloxone and overdose risks in general (28) .
Population level responses are required to reverse the increasing number of opioid overdoses. The increasing number of opioid overdoses in Australia include pharmaceutical opioids as well as heroin. As the primary distributers of pharmaceutical opioids in our communities, pharmacists are increasingly being recognised as potential educators and distributers of naloxone (4, 5, 11, 12) . The down-scheduling enables members of the public to request naloxone from pharmacies but also for pharmacists to initiate naloxone supply. Training and supply issues identified in this study suggests that pharmacists require more support if their potential role in overdose prevention is to be realised.
Limitations
There are some limitations to consider in interpreting these findings. Not all pharmacists responded, though from our random sample, participant demographics represented that pharmacists were broadly representative. Females in this sample were slightly underrepresented with females representing 61% of registered pharmacists in Australia as of September 2015 (22). The distribution of pharmacists by state and age was representative of the national distribution (22). There is the potential for social desirability bias relating to self-reported data. To minimize this effect data collection for the online survey was anonymous and participants from interviews were informed that their data would be de-identified (8, 29) . The question examining further training in substance use disorders was limited in that we did not capture details on the extent of the training, or when it occurred. Future studies may capture greater detail to allow a more detailed examine of this aspect. Further, the qualitative project sample was self-selected and findings may not be generalizable across all pharmacists. Finally, the online data were collected prior to rescheduling, and the qualitative data were collected after, meaning that 
